×

Delsie Braganza

Delsie joined the Focal Point Research team in 2011 and has been an invaluable asset for our clients. With her strong regulatory and quality assurance background, she is able to help clients understand the Canadian and US requirements, set targets to achieve compliance, and attain their goals to get products to market.

Delsie is able to audit facilities, set up and maintain GMP compliant facilities, develop strong quality management systems, and co-ordinate successful Health Canada inspections. In addition to this, Delsie oversees all regulatory compliance reviews and submissions made to Health Canada and the US FDA.

Delsie obtained an Honours Bachelor of Science (Hons. B. Sc.) in Pharmaceutical Chemistry from the University of Toronto, Post-Graduate Certificate in Pharmaceutical Regulatory Affairs and Quality Operations (RAQ) from Seneca College and Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS).

When she’s not learning something new, Delsie loves spending time with family, going on road trips or long walks, and swimming.

×

Jennifer Porter, BA Psychology, MBA – President & CEO

​Having started at Focal Point Research in 2011, Jenn has been fully engaged in the company and since day one, has leveraged her MBA and interest in the regulated products industries to grow her passion for the business and services offered. 

Jenn has excelled at building on initial conversations with a variety of companies from all industries seeking regulatory and quality assurance services. She has developed strong relationships with each client, offering each one a unique opportunity to have the Focal Point Research team help them develop successful strategies and bring products to market, while ensuring their compliance needs are being fulfilled. 

Jenn has not only been a leader internally, but a key contact for all clients and in 2021, Jenn was the obvious choice to lead Focal Point Research into the future as the successor to company founder, Rob Fichtner.

Jennifer balances her career by honouring her wanderlust, spending her leisure time golfing, and enjoying the outdoors with her loving dog.

×

Robert Fichtner

Since co-founding Focal Point over 20 years ago, Rob has led our Regulatory and Scientific practice. A chemist by training, his experience includes Cosmetics, Drugs, Medical Devices, Consumer Products and Natural Health Products (Dietary Supplements). Rob has participated in the launch of thousands of products including their formulation, manufacturing and regulatory submissions for approval. His wealth of experience spans almost 40 years in innovation.
Rob has been involved in all aspects of innovation and new product development. He shares some of his insights in his new video series “Lectures in Innovation”. You can view the first video here.
When not supporting innovators, Rob spends his time becoming a better sailor and guitar player.

(905) 271 2709 mail@focalpointresearch.net
Focal Point
  • Home
  • About
  • Team
  • Services
    • Cosmetic Consultants
      • Natural Health Products
      • Topical OTC Drugs
      • Medical Devices
      • Consumer Products
      • Technology
      • FDA Consulting
    • Health Canada Consultants
      • Regulatory Affairs
      • Pharmacovigilance Services
      • MoCRA
      • Ingredient Compliance
      • CEPA
  • Innovation
  • Articles
  • Contact
Select Page
Health Canada’s proposed updates to the MDEL guidance documents

Health Canada’s proposed updates to the MDEL guidance documents

by Srishti Chaudhari | Mar 25, 2024 | Canadian Quality Assurance, Canadian Regulatory, Medical Devices

The proposed amendments to the Medical Device Regulations (MDR) would allow Health Canada to impose Terms and Conditions (T&Cs) on Medical Device Establishment Licences (MDEL) at anytime during the licence lifecycle. This policy is drafted in order to provide...
NHP Monograph Revisions Batch 2 open for comments!

NHP Monograph Revisions Batch 2 open for comments!

by Srishti Chaudhari | Mar 25, 2024 | Canadian Quality Assurance, Canadian Regulatory, Natural Health Products

The Natural Non-Prescription Health Products Directorate (NNHPD) began revising the NHP monographs in October 2023 with an objective to modernize the monographs, ensuring they meet the new NHP labeling requirements. The consultation period for the Batch 1 monographs...
Are you CEPA compliant? 

Are you CEPA compliant? 

by Srishti Chaudhari | Mar 19, 2024 | Canadian Quality Assurance, Canadian Regulatory

The Canada Environmental Protection Act (CEPA, 1999) regulates toxic substances under the Prohibition of Certain Toxic Substances Regulations. This oversight is for safeguarding the environment and human health. These regulations prohibit the manufacture, use, sale,...
Washington’s new cosmetic law!

Washington’s new cosmetic law!

by Srishti Chaudhari | Mar 19, 2024 | Cosmetics, U.S. Regulatory

Washington State has introduced a new law under The Toxic-Free Cosmetics Act that could impact your product portfolio. Applicable from January 1, 2025, this law will restrict the manufacture, distribution, and sale of cosmetic products that contain one or more of...
Health Canada to update Cosmetic Ingredient Hotlist for AHAs

Health Canada to update Cosmetic Ingredient Hotlist for AHAs

by Srishti Chaudhari | Mar 19, 2024 | Canadian Quality Assurance, Canadian Regulatory, Cosmetics

After six years of consultations and stakeholder engagement, Health Canada is proceeding with updating the Cosmetic Ingredient Hotlist for Alpha-Hydroxy Acids (AHAs). The proposed update aligns with the 2023 consultation proposal, with minor adjustments. AHAs were...
« Older Entries
Next Entries »

Recent Posts

  • Canadian Cosmetic Hotlist Updates
  • Changes to the Canadian Cosmetic Notification (CNF) form requirements as of October 9, 2024
  • Extension of Comment Period for Proposed Amendment to Section 25705(b) on Safe Exposure Levels for Titanium Dioxide Under Proposition 65
  • Update: Final Amendments to the Charter of the French Language regulations published today
  • Proposition 65 – Notice of Modification: Amendments to Clear and Reasonable Warnings Safe Harbor Methods and Content

Recent Comments

    Archives

    • March 2025
    • October 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • December 2023
    • November 2023
    • September 2023
    • August 2023
    • July 2023
    • June 2023
    • January 2023
    • December 2022
    • November 2022
    • July 2022
    • June 2022
    • April 2022
    • March 2022
    • October 2021
    • July 2021
    • April 2021
    • March 2021
    • February 2021
    • January 2021
    • November 2020
    • October 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • April 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • November 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • May 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • May 2018
    • April 2018
    • March 2018
    • February 2018
    • January 2018

    Categories

    • California Cosmetic Regulations
    • California Office of Environmental Health Hazard Assessment
    • Canadian Quality Assurance
    • Canadian Regulatory
    • Cosmetics
    • Cosmetics
    • Environment and Climate Change Canada
    • European Regulatory
    • Events/Company Updates
    • FDA
    • Federal Plastics Registry
    • Importation of NHPs
    • Innovation
    • Medical Device
    • Medical Devices
    • MoCRA
    • Natural Health Products
    • OTC Drugs
    • Our View
    • Research/Science/Technology
    • U.S. Regulatory
    • U.S. State Updates
    • Uncategorized
    Copyright © 2025 Focal Point Research Inc.
    Privacy Policy | Terms of Use
    Website Design and Development by PLAY